United States
Every company in the roster headquartered in United States.
Every company in the roster headquartered in United States.
441 of 441 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Adiso TherapeuticsPrivate | 1 asset: 1 Ph 1 | PegmispotidePhase 1 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
ADvantage TherapeuticsPrivate | 1 asset: 1 Ph 2 | AD04Phase 2 · Alzheimer's Disease | Dec 2026AD04 · Phase 2 | — | — | — | — |
AgeneBioPrivate | 1 asset: 1 Ph 3 | AGB101Phase 2/3 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
AirNexis TherapeuticsPrivate | 1 asset: 1 Ph 3 | HSK39004Phase 3 · Chronic Obstructive Pulmonary Disease | 11 Jun 2027HSK39004 · Phase 3 | — | — | — | — |
Akros PharmaPrivate | 1 asset: 1 Ph 2 | JTT-861Phase 2 · Heart FailurePartial signal | None on record | — | — | — | — |
AllRock BioPrivate | 1 asset: 1 Ph 2 | ROC-101Phase 2 · Pulmonary Arterial Hypertension | Mar 2027ROC-101 · Phase 2 | — | — | — | — |
Allyx TherapeuticsPrivate | 1 asset: 1 Ph 1 | BMS-984923Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Alterome Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | ALTA3263Phase 1 · Non-Small Cell Lung Cancer | May 2029ALTA3263 · Phase 1 | — | — | — | — |
AltruBioPrivate | 1 asset: 1 Ph 2 | ALTB-268Phase 2 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
Anwita Biosciences, Inc.Private | 1 asset: 1 Ph 1 | AWT020Phase 1 · Non-Small Cell Lung Cancer | 30 Apr 2028AWT020 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | BucindololPhase 2 · Heart FailurePartial signal | None on record | — | — | — | — | |
Areteia TherapeuticsPrivate | 1 asset: 1 Ph 2 | dexpramipexolePhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signal | None on record | — | — | — | — |
Artery TherapeuticsPrivate | 1 asset: 1 Ph 1 | CS6253Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Asher Biotherapeutics, Inc.Private | 1 asset: 1 Ph 1 | Etakafusp alfaPhase 1 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Athos TherapeuticsPrivate | 1 asset: 1 Ph 2 | ATH-063Phase 2 · Ulcerative ColitisWeak signal | 14 Dec 2028ATH-063 · Phase 2 | — | — | — | — |
Auricula Biosciences Inc.Private | 1 asset: 1 Ph 2 | WEF-001Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2028WEF-001 · Phase 1/2 | — | — | — | — |
Avenzo Therapeutics, Inc.Private | 3 assets: 3 Ph 2 | AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 31 Jan 2028AVZO-021 · Phase 1/2 | — | — | — | — |
Avobis BioPrivate | 1 asset: 1 Ph 2 | AVB-114Phase 2 · Crohn's DiseasePartial signal | None on record | — | — | — | — |
Azurity PharmaceuticalsPrivate | 10 assets: 10 approved | Approved assets only | Sep 2027Zonisamide (Zonisade) · Approved | — | — | — | — |
Biomed IndustriesPrivate | 1 asset: 1 Ph 2 | NA-931Phase 2 · ObesityPartial signal | 15 Aug 2027NA-931 · Phase 2 | — | — | — | — |
Boston OncologyPrivate | 2 assets: 2 Ph 3 | BireociclibPhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | None on record | — | — | — | — |
Calico Life Sciences LLCPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | FosigotifatorPhase 2/3 | Nov 2027Fosigotifator · Phase 1/2 | — | — | — | — |
cAMPfield TherapeuticsPrivate | 1 asset: 1 Ph 3 | Prifemilast (HPP737)Phase 3 · PsoriasisPartial signal | None on record | — | — | — | — |
Cardurion PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | TovinontrinePhase 2 · Heart FailurePartial signal | None on record | — | — | — | — |
Cenna BiosciencesPrivate | 1 asset: 1 Ph 1 | 8M2DPhase 1 · Alzheimer's Disease | Sep 20278M2D · Phase 1 | — | — | — | — |
Cirius TherapeuticsPrivate | 1 asset: 1 Ph 2 | AzemiglitazonePhase 2 · Type 2 Diabetes | None on record | — | — | — | — |
Clasp Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CLSP-5282Phase 1 · Non-Small Cell Lung Cancer | May 2029CLSP-5282 · Phase 1 | — | — | — | — |
ConSynance TherapeuticsPrivate | 1 asset: 1 Ph 2 | CSTI-500Phase 2 · Prader-Willi SyndromeWeak signal | Jun 2027CSTI-500 · Phase 2 | — | — | — | — |
CordavisPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
CREATE MedicinesPrivate | 2 assets: 2 Ph 1 | MT-302Phase 1 · Non-Small Cell Lung Cancer | 31 Jan 2027MT-304 · Phase 1 | — | — | — | — |
Crossbow Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CBX-250Phase 1 · Acute Myeloid Leukemia | Jan 2027CBX-250 · Phase 1 | — | — | — | — |
Direct BiologicsPrivate | 1 asset: 1 Ph 2 | ExoFloPhase 2 · Crohn's DiseaseWeak signal | Jun 2027ExoFlo · Phase 2 | — | — | — | — |
Encore DermatologyPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
ERX PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | ERX1000Phase 2 · ObesityWeak signal | May 2027ERX1000 · Phase 2 | — | — | — | — |
Esperion TherapeuticsPrivate | 2 assets: 2 approved | Approved assets only | None on record | — | $156MMar 2026 | ~6.2 qtrs | $44M |
| 1 asset: 1 Ph 2 | FMC-376Phase 1/2 · Non-Small Cell Lung Cancer | Oct 2027FMC-376 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | Gemcitabine (FF-10832)Phase 2 · Non-Small Cell Lung Cancer | May 2029Gemcitabine (FF-10832) · Phase 2 | — | — | — | — | |
Gilgamesh PharmaPrivate | 1 asset: 1 Ph 2 | BlixeprodilPhase 2 · Major Depressive DisorderWeak signal | None on record | — | — | — | — |
GluBio Therapeutics Inc.Private | 1 asset: 1 Ph 1 | GLB-001Phase 1 · Acute Myeloid Leukemia | None on record | — | — | — | — |
Halia TherapeuticsPrivate | 1 asset: 1 Ph 2 | HT-4253Phase 2 · Alzheimer's Disease | Feb 2028HT-4253 · Phase 2 | — | — | — | — |
Humanetics CorporationPrivate | 1 asset: 1 Ph 2 | BIO 300Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
HUYABIO International, LLC.Private | 5 assets: 2 Ph 3, 1 Ph 2, 2 Ph 1 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 30 Dec 2026GH21 · Phase 2 | — | — | — | — |
Iambic Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | IAM1363Phase 1/2 · Non-Small Cell Lung Cancer | Oct 2028IAM1363 · Phase 1/2 | — | — | — | — |
iCell Gene TherapeuticsPrivate | 4 assets: 1 Ph 2, 3 Ph 1 | ICG318Phase 2 · Systemic Lupus Erythematosus | 31 Dec 2027ICG318 · Phase 1 | — | — | — | — |
Imbria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NinerafaxstatPhase 2 · Heart FailureWeak signal | Dec 2026Ninerafaxstat · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 1 | KB-GDT-01Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
Immunophotonics, Inc.Private | 1 asset: 1 Ph 3 | N-dihydrogalactochitosanPhase 2/3 · Colorectal Cancer | Dec 2033N-dihydrogalactochitosan · Phase 2/3 | — | — | — | — |
Incendia TherapeuticsPrivate | 1 asset: 1 Ph 1 | EnsavatatugPhase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
InduPro, Inc.Private | 1 asset: 1 Ph 2 | IDP-001Phase 1/2 · Non-Small Cell Lung Cancer | Jun 2028IDP-001 · Phase 1/2 | — | — | — | — |
Integro TheranosticsPrivate | 1 asset: 1 Ph 2 | Cronexitide lanocianinePhase 2 · Non-Small Cell Lung Cancer | Jun 2027Cronexitide lanocianine · Phase 2 | — | — | — | — |
Intra-Cellular TherapiesPrivate | 2 assets: 1 approved, 1 Ph 3 | DeulumateperonePhase 3 · Generalized Anxiety Disorder | 16 Mar 2027Deulumateperone · Phase 2 | — | — | — | — |
IntralytixPrivate | 1 asset: 1 Ph 2 | EcoActivePhase 1/2 · Crohn's Disease | None on record | — | — | — | — |
Jina PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | nanosomal tacrolimusPhase 2 · Ulcerative Colitis | None on record | — | — | — | — |
KaliVir ImmunotherapeuticsPrivate | 1 asset: 1 Ph 1 | VET3-TGIPhase 1 · Non-Small Cell Lung Cancer | 30 Sep 2027VET3-TGI · Phase 1 | — | — | — | — |
Kestrel TherapeuticsPrivate | 1 asset: 1 Ph 1 | KST-6051Phase 1 · Non-Small Cell Lung Cancer | Apr 2028KST-6051 · Phase 1 | — | — | — | — |
Keystone Nano, IncPrivate | 1 asset: 1 Ph 1 | Ceramide NanoLiposome (Ceraxa)Phase 1 · Acute Myeloid Leukemia | 30 Jan 2027Ceramide NanoLiposome (Ceraxa) · Phase 1 | — | — | — | — |
Kinaset TherapeuticsPrivate | 1 asset: 1 Ph 2 | frevecitinibPhase 2 · AsthmaWeak signal | 30 Nov 2027frevecitinib · Phase 2 | — | — | — | — |
Kindeva Drug DeliveryPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Kivu Bioscience Inc.Private | 1 asset: 1 Ph 1 | KIVU-107Phase 1 · Non-Small Cell Lung Cancer | 31 Mar 2028KIVU-107 · Phase 1 | — | — | — | — |
LAPIX TherapeuticsPrivate | 1 asset: 1 Ph 1 | LPX-TI641Phase 1 · Psoriatic Arthritis | None on record | — | — | — | — |
Libella Gene TherapeuticsPrivate | 1 asset: 1 Ph 1 | AAV-hTERTPhase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Lighthouse PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | LHP588Phase 2 · Alzheimer's Disease | 31 Jan 2029LHP588 · Phase 2 | — | — | — | — |
Linnaeus Therapeutics, Inc.Private | 1 asset: 1 Ph 3 | LNS8801Phase 2/3 · Melanoma | Feb 2029LNS8801 · Phase 2/3 | — | — | — | — |
| 1 asset: 1 Ph 1 | LonitoclaxPhase 1 · Acute Myeloid Leukemia | Dec 2026Lonitoclax · Phase 1 | — | — | — | — | |
Marengo Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | Invikafusp alfaPhase 1/2 · Non-Small Cell Lung Cancer | Jan 2027Invikafusp alfa · Phase 1/2 | — | — | — | — |
Medunik USAPrivate | 1 asset: 1 approved | Approved assets only | Feb 2028Hydroxyurea (Siklos) · Phase 2 | — | — | — | — |
Memgen, Inc.Private | 1 asset: 1 Ph 1 | MEM-288Phase 1 · Non-Small Cell Lung Cancer | Feb 2027MEM-288 · Phase 1 | — | — | — | — |
Mirador TherapeuticsPrivate | 2 assets: 2 Ph 2 | MT-201Phase 2 · Ulcerative Colitis | 30 Apr 2027MT-501 · Phase 2 | — | — | — | — |
MTI Biotech Inc.Private | 1 asset: 1 Ph 2 | 2-hydroxybenzylamine acetatePhase 1/2 · Alzheimer's Disease | 30 Dec 20282-hydroxybenzylamine acetate · Phase 1/2 | — | — | — | — |
NeoImmuneTechPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | TraneurocinPhase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — | |
Neuronascent, Inc.Private | 1 asset: 1 Ph 1 | NNI-362Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
NeuroPro Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | NPT2042Phase 2 · EpilepsyPartial signal | None on record | — | — | — | — |
NeuroTherapia, Inc.Private | 1 asset: 1 Ph 2 | NTRX-07Phase 2 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Newave Pharmaceutical IncPrivate | 1 asset: 1 Ph 1 | NexatoclaxPhase 1 · Acute Myeloid Leukemia | 31 Dec 2026Nexatoclax · Phase 1 | — | — | — | — |
NGM BiopharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NGM707Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | $61MDec 2023 | Ended Feb 2024 | $118M |
Nimbus Saturn, Inc.Private | 1 asset: 1 Ph 2 | NDI-101150Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
NImmune BiopharmaPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | omilancorPhase 2 · Ulcerative ColitisPartial signal | None on record | — | — | — | — |
Normunity AccelCo, Inc.Private | 1 asset: 1 Ph 1 | NRM-823Phase 1 · Non-Small Cell Lung Cancer | 30 May 2027NRM-823 · Phase 1 | — | — | — | — |
NSC-TherapeuticsPrivate | 1 asset: 1 Ph 2 | NSC001Phase 1/2 · Alzheimer's Disease | None on record | — | — | — | — |
Nuravax, Inc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | AV-1959RPhase 2 · Alzheimer's DiseaseWeak signal | 1 Apr 2027DUVAX · Phase 1 | — | — | — | — |
Odyssey TherapeuticsPrivate | 1 asset: 1 Ph 2 | OD-07656Phase 2 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
Oligomerix, IncPrivate | 1 asset: 1 Ph 1 | OLX-07010Phase 1 · Alzheimer's Disease | None on record | — | — | — | — |
Onchilles Pharma IncPrivate | 1 asset: 1 Ph 2 | N17350Phase 1/2 · Non-Small Cell Lung Cancer | Jul 2028N17350 · Phase 1/2 | — | — | — | — |
OncoC4, Inc.Private | 2 assets: 1 Ph 3, 1 Ph 1 | GotistobartPhase 3 · Non-Small Cell Lung Cancer | 30 Nov 2026Gotistobart · Phase 1/2 | — | — | — | — |
OrsoBioPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | TLC-2716Phase 2 · Hypertriglyceridemia | None on record | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
PAQ Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | PT0511Phase 1 · Non-Small Cell Lung Cancer | 18 Oct 2028PT0511 · Phase 1 | — | — | — | — |
Paragon TherapeuticsPrivate | 1 asset: 1 Ph 1 | APG808Phase 1 · Chronic Obstructive Pulmonary Disease | None on record | — | — | — | — |
Partner Therapeutics, Inc.Private | 2 assets: 2 approved | Approved assets only | 31 Dec 2026Zenocutuzumab · Phase 2 | — | — | — | — |
Phanes TherapeuticsPrivate | 1 asset: 1 Ph 2 | MavrostobartPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027Mavrostobart · Phase 1/2 | — | — | — | — |
PharmatrophiXPrivate | 1 asset: 1 Ph 2 | LM11A-31Phase 1/2 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Plexium, Inc.Private | 1 asset: 1 Ph 1 | PLX-61639Phase 1 · Non-Small Cell Lung Cancer | Dec 2029PLX-61639 · Phase 1 | — | — | — | — |
Population CouncilPrivate | 1 asset: 1 Ph 3 | DapivirinePhase 3 · HIVReliable signal | None on record | — | — | — | — |
PulmovantPrivate | 1 asset: 1 Ph 3 | MosliciguatPhase 3 · Pulmonary Hypertension Associated with Interstitial Lung Disease | Dec 2026Mosliciguat · Phase 2 | — | — | — | — |
Pyros PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Radius PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | Nov 2026Elacestrant · Phase 2 | — | — | — | — |
Rare Disease TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
ReAlta Life SciencesPrivate | 1 asset: 1 Ph 2 | PegtarazimodPhase 2 · Chronic Obstructive Pulmonary Disease | Dec 2026Pegtarazimod · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 2 | RB-ADSCPhase 2 · Alzheimer's Disease | Sep 2028RB-ADSC · Phase 1 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.